Medicinal Chemistry News and Research RSS Feed - Medicinal Chemistry News and Research

Flexible Solution for High Throughput Evaporation

Flexible Solution for High Throughput Evaporation

Genevac Series 3 HT evaporators provide an ideal solution for evaporation bottlenecks in high throughput medicinal chemistry, natural product and production laboratories that generate large numbers of samples for processing. [More]
New study improves understanding of metal-based chemotherapy drugs

New study improves understanding of metal-based chemotherapy drugs

What is the mechanism of action of metal-based chemotherapy drugs (the most widely used for treating common cancers like testicular or ovarian cancer)? How can we improve their effect and reduce their toxicity? A new study combining experiments and theory has broadened our knowledge of the molecular mechanisms of these active drugs to help experimentalists devising increasingly effective drugs with fewer side effects. [More]
TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

Findings from a new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) suggest a potent new therapeutic approach for a number of hard-to-treat breast cancers. [More]
New funding supports research on new and improved drug treatments for tuberculosis, malaria

New funding supports research on new and improved drug treatments for tuberculosis, malaria

University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases -- thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation. [More]
SLU scientist awarded new $2.2 million NIH grant to develop cure for hepatitis B

SLU scientist awarded new $2.2 million NIH grant to develop cure for hepatitis B

With proof-of-principle in his pocket and a new $2.2 million grant from the National Institutes of Health, SLU scientist John Tavis, Ph.D., will take his 25 year mission to finally develop a cure for the hepatitis B virus into the next phase. [More]
Vagus nerve stimulation prevents hemorrhagic complications following surgery

Vagus nerve stimulation prevents hemorrhagic complications following surgery

Stimulating the vagus nerve is a potentially efficacious and safe way to stop the flow of blood and prevent hemorrhagic complications following surgery and other invasive procedures, according to a researcher in the Center for Bioelectronic Medicine at The Feinstein Institute for Medical Research. [More]
Novel class of antimicrobials could be effective in fighting drug-resistant MRSA infection

Novel class of antimicrobials could be effective in fighting drug-resistant MRSA infection

A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University. [More]
Innovative compound with anti-MRSA qualities may help develop new class of antibiotics

Innovative compound with anti-MRSA qualities may help develop new class of antibiotics

With global health services increasingly worried about the rise of antibiotic resistant diseases, researchers at Maynooth University have discovered a compound whose anti-MRSA qualities pave the way for the development of a new class of antibiotics. [More]
Scientists develop potent compound that promotes wakefulness, remedies sleep disorder narcolepsy

Scientists develop potent compound that promotes wakefulness, remedies sleep disorder narcolepsy

Hiroshi Nagase, a Professor at the International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, collaborated with Masashi Yanagisawa (Professor / Director of WPI-IIIS) and successfully developed a potent compound that promotes wakefulness and remedies the sleep disorder narcolepsy in model animals. [More]
Drug compounds target multiple pathways associated with myotonic dystrophy type 1

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

Efforts to treat myotonic dystrophy type 1, the most common form of muscular dystrophy, are in their infancy. In a new study, researchers report they have added new capabilities to an experimental drug agent that previously defeated only one of DM1's many modes of action. Their retooled compounds interrupt the disease's pathology in three ways. [More]
University of Kansas professor recognized with MERIT Award

University of Kansas professor recognized with MERIT Award

Emily Scott, professor of medicinal chemistry at the University of Kansas, has been recognized with a MERIT Award from the National Institutes of Health's National Institute of General Medical Sciences. It's a rare and important recognition -- researchers can receive them only once in a career. [More]
Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

Resistance to chemotherapy is a major problem for those suffering from ovarian cancer--a problem that prevents a cure from a disease dubbed the "silent killer." University of Georgia researchers are giving patients new hope with recent findings that help pinpoint the mechanisms causing chemoresistance. [More]
Future Medicinal Chemistry releases themed issue higlighting the Academic Drug Discovery conference

Future Medicinal Chemistry releases themed issue higlighting the Academic Drug Discovery conference

Future Medicinal Chemistry, a leading MEDLINE-indexed journal published by Future Science Group, has released a themed issue dedicated to providing coverage of the presentations that took place at the 2015 Academic Drug Discovery Conference (Cambridge, UK), organized by SelectBio. [More]

New manganese-based catalyst may accelerate drug discovery, development

Chemists have long believed that inserting nitrogen -- a beneficial ingredient for making many pharmaceuticals and other biologically active molecules -- into a carbon-hydrogen bond requires a trade-off between catalyst reactivity and selectivity. [More]
Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic. [More]
Virginia Tech scientists discover new treatments to target antibiotic-resistant bacteria

Virginia Tech scientists discover new treatments to target antibiotic-resistant bacteria

Virginia Tech researchers have discovered a new group of antibiotics that may provide relief to some of the more than 2 million people in the United States affected by antibiotic resistance. [More]
Researchers one step closer to developing synthetic and cheaper antivenoms

Researchers one step closer to developing synthetic and cheaper antivenoms

Researchers involved in an international collaboration across six institutions, including the University of Copenhagen and the National Aquarium of Denmark (Den Blå Planet), have successfully identified the exact composition of sea snake venom, which makes the future development of synthetic antivenoms more realistic. [More]
AMSBIO launches PATHM2 libraries for small scale screening in developmental biology, discovery research

AMSBIO launches PATHM2 libraries for small scale screening in developmental biology, discovery research

AMSBIO has announced the launch of PATHM2 small molecules libraries for small scale screening in developmental biology and discovery research. [More]
Researchers successfully use alcohols as reagents in alkylation reaction

Researchers successfully use alcohols as reagents in alkylation reaction

Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups--fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery--onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies. [More]
Brain scans may help predict patients' response to antipsychotic drug treatment

Brain scans may help predict patients' response to antipsychotic drug treatment

Investigators at The Feinstein Institute for Medical Research have discovered that brain scans can be used to predict patients' response to antipsychotic drug treatment. The findings are published online in the latest issue of The American Journal of Psychiatry. [More]
Advertisement
Advertisement